Home » Stocks » Generex Biotechnology

Generex Biotechnology Corp. (GNBT)

Stock Price: $0.228 USD 0.017 (8.06%)
Updated Oct 21, 2020 3:44 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 20.95M
Revenue (ttm) 2.03M
Net Income (ttm) -26.45M
Shares Out 91.88M
EPS (ttm) -0.41
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 21, 2020
Last Price $0.228
Previous Close $0.211
Change ($) 0.017
Change (%) 8.06%
Day's Open 0.208
Day's Range 0.208 - 0.230
Day's Volume 293,489
52-Week Range 0.165 - 1.87

More Stats

Market Cap 20.95M
Enterprise Value n/a
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 91.88M
Float 37.60M
EPS (basic) n/a
EPS (diluted) -0.41
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 211,981
Short Ratio 1.73
Short % of Float 0.56%
Beta -2.86
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 10.33
PB Ratio n/a
Revenue 2.03M
Operating Income n/a
Net Income -26.45M
Free Cash Flow n/a
Net Cash n/a
Net Cash / Share n/a
Gross Margin 101.88%
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -23.89%
ROE -370.08%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

Current: $0.228
Target: 204.08
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial Overview

No financial data available for this stock yet.

Company Profile

Company Details

Full Name Generex Biotechnology Corp.
Country United States
Employees 17
CEO Joseph Moscato

Stock Information

Ticker Symbol GNBT
Stock Exchange US OTC
Sector Healthcare
Industry Biotechnology
Unique Identifier OTCMKTS: GNBT


Generex Biotechnology Corporation, through its subsidiaries, engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. It offers Generex Oral-lyn, an oral insulin product. The company is also developing AE37, a synthetic peptide vaccine, which has completed Phase IIb clinical trial to stimulate a potent and specific immune response against tumors expressing the HER-2/neu oncogene in patients with breast cancer and prostate cancer. In addition, it develops, manufactures, and distributes rapid point-of-care in-vitro medical diagnostics for infectious diseases, such as human immunodeficiency virus, tuberculosis, malaria, hepatitis B, hepatitis C, syphilis, and others; and test kits and cassettes for testing infectious diseases, as well as Excellagen, a wound conforming gel. Further, the company is developing immunotherapeutic products and vaccines; and extracellular matrix hydrogel solution, a tissue engineered therapy for the treatment of Ulcerative Colitis. Additionally, it manufactures and sells foot and ankle kits with surgical plates, screws, and tools; and distributes surgical supplies, orthopedic implants, and biologics, including human placental derived tissue products for regenerative medicine applications. It also serves as the general partner of the Management Services Organization. Generex Biotechnology Corporation was founded in 1983 and is headquartered in Miramar, Florida.